Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Bactiguard Holding AB's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 41.95.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bactiguard Holding AB's liquidation value for the
three
months ended in Jun. 2026 was kr-142.9 Mil.
Bactiguard Holding AB (CHIX:BACTBs) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Bactiguard Holding AB's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB Change In Receivables Related Terms
Bactiguard Holding AB Change In Receivables Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of kr8.5 Mil mean?
Bactiguard Holding AB (CHIX:BACTBS) has a Change In Receivables of kr8.5 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Bactiguard Holding AB and its competitors.
Is Bactiguard Holding AB's Change In Receivables too high?
Bactiguard Holding AB's current Change In Receivables is kr8.5 Mil. Overall, Bactiguard Holding AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Change In Receivables compare to ABT and SYK?
Bactiguard Holding AB's Change In Receivables of kr8.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for Bactiguard Holding AB and its competitors. Bactiguard Holding AB's current Change In Receivables is kr8.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Change In Receivables of kr8.5 Mil. The stock's GF Value™ is kr246.25, compared to a current price of kr128.60 — trading 47.8% below its estimated fair value. The current Change In Receivables is kr8.5 Mil. Bactiguard Holding AB's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Change In Receivables is kr8.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 47.8% below its estimated GF Value™ of kr246.25.
Key valuation signals for CHIX:BACTBS:
Change In Receivables: kr8.5 Mil
GF Value™: kr246.25 vs. price of kr128.60 (47.8% below fair value)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
63GF Score
Get the complete analysis for CHIX:BACTBS
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
